Supplemental data

Supplementary table 1 Summary of clinical efficacy of placebo switchers* through Week 104 in overall population

Efficacy endpoints	Week 52		Week 104	
	Placebo-300 mg (N=153)	Placebo-150 mg (N=153)	Placebo-300 mg (N=153)	Placebo-150 mg-300 mg (N=153)
ACR20 response, % (n)	74.6 (126)	71.9 (128)	73.5 (117)	76.4 (123)
ACR50 response, % (n)	50 (126)	46.1 (128)	53.8 (117)	53.7 (123)
ACR70 response, % (n)	29.4 (126)	28.1 (128)	37.6 (117)	36.6 (123)
PASI 90 response$^{\beta}$, % (n)	53.8 (65)	47.5 (61)	66.7 (63)	57.6 (59)
PASI 100 response$^{\beta}$, % (n)	32.3 (65)	36.1 (61)	50.8 (63)	42.4 (59)
DAS28-CRP score, mean change from BL±SD (n)	−2.0±1.2 (125)	−1.8±1.3 (128)	−2.2±1.3 (116)	−1.9±1.3 (121)
HAQ-DI score, mean change from BL±SD (n)	−0.5±0.5 (127)	−0.5±0.6 (127)	−0.6±0.5 (119)	−0.5±0.6 (122)
Enthesitis resolution$^{\#}$, % (n)	69 (71)	67.1 (79)	73.1 (67)	69.7 (76)
Dactylitis resolution$^{\#}$, % (n)	84.6 (39)	73.2 (56)	87.5 (40)	84.9 (53)

Results are reported as observed data.

*Placebo switchers are patients originally randomized to placebo who switched to secukinumab.
n, number of patients in the treatment group with evaluation at Weeks 52 and 104; N, number of randomized patients; %, percentage of responses. ACR, American College of Rheumatology response criteria; BL, baseline; DAS28-CRP, 28-joint Disease Activity Score using C reactive protein; HAQ-DI,

HAQ-Disability Index; PASI, Psoriasis Area and Severity Index; SD, standard deviation.
[§]150 mg groups include patients who escalated to 300 mg.
[β]Analysis performed in randomized patients with psoriasis (psoriasis subset) affecting ≥3% body surface area at baseline; N=78 (placebo-300 mg), 74 (placebo-150 mg).
[#]Resolution of enthesitis and dactylitis are shown for patients with the symptoms at baseline.

Supplementary table 2 Summary of clinical efficacy at Week 104 by prior anti-TNF therapy status

Efficacy endpoints	Anti-TNF-naïve			Anti-TNF-IR		
	300 mg N=154 % (n)	150 mg N=153 % (n)	150 mg no load N=157 % (n)	300 mg N=68 % (n)	150 mg N=67 % (n)	150 mg no load N=65 % (n)
ACR20 response	78.1 (137)	81.8 (132)	80.8 (125)	74 (50)	72.1 (43)	69.8 (43)
ACR50 response	54 (137)	59.8 (132)	61.6 (125)	46 (50)	30.2 (43)	46.5 (43)
PASI 90 response	70.6 (68)	65.5 (84)	65.8 (73)	69 (29)	31.6 (19)	50 (18)
DAS28-CRP score, mean change from BL	−2.1 (133)	−2.1 (129)	−2.2 (123)	−2.1 (49)	−1.9 (43)	−2.1 (42)
HAQ-DI score, mean change from BL	−0.6 (137)	−0.6 (134)	−0.7 (126)	−0.6 (49)	−0.6 (43)	−0.5 (43)
Enthesitis resolution	79.5 (88)	82.4 (85)	72.5 (69)	73.3 (30)	75 (32)	61.5 (26)
Dactylitis resolution	87.5 (48)	86 (43)	90.3 (62)	68.8 (16)	84.2 (19)	84.6 (13)

Results are reported as observed data.

n, number of patients in the treatment group with evaluation at Week 104; %, percentage of responses.

ACR, American College of Rheumatology response criteria; BL, baseline; DAS28-CRP, 28-joint Disease Activity Score using C reactive protein; HAQ-DI, HAQ-Disability Index; IR, inadequate response; PASI, Psoriasis Area and Severity Index; TNF, tumor necrosis factor.

150 mg and 150 mg no load groups include patients who escalated to 300 mg.

Supplementary table 3 ACR responses up to 40 weeks after dose escalation from secukinumab 150 mg to 300 mg in anti-TNF-naïve patients

ACR response	Before dose-escalation	After dose-escalation			
	(%)	12-16 weeks (%)	20-24 weeks (%)	28-32 weeks (%)	36-40 weeks (%)
ACR < 20 (No response)	36	24	26	25	27
20 ≤ ACR < 50	36	28	28	33	28
50 ≤ ACR < 70	11	25	26	18	23
ACR ≥ 70	18	24	21	25	23

'Before dose-escalation' was defined as the last assessment on or before the patient took the escalated dose. Number of patients included in the analysis (N=101).

ACR, American College of Rheumatology response criteria; TNF, tumor necrosis factor.

Supplementary table 4 ACR responses up to 40 weeks after dose escalation from secukinumab 150 mg to 300 mg in anti-TNF-IR patients

ACR response	Before dose-escalation	After dose-escalation			
	(%)	12-16 weeks (%)	20-24 weeks (%)	28-32 weeks (%)	36-40 weeks (%)
ACR < 20 (No response)	53	47	44	36	33
20 ≤ ACR < 50	31	22	22	33	25
50 ≤ ACR < 70	6	3	14	11	25
ACR ≥ 70	11	28	19	19	17

'Before dose-escalation' was defined as the last assessment on or before the patient took the escalated dose. Number of patients included in the analysis (N=36); IR, inadequate response; TNF, tumor necrosis factor.